Compare DFH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | IMMX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.1M | 784.8M |
| IPO Year | 2020 | 2021 |
| Metric | DFH | IMMX |
|---|---|---|
| Price | $9.00 | $8.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | N/A | ★ $24.30 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $2.85 |
| 52 Week High | $23.80 | $15.10 |
| Indicator | DFH | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 36.11 |
| Support Level | $7.30 | $7.96 |
| Resistance Level | $16.47 | $8.97 |
| Average True Range (ATR) | 0.61 | 0.53 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 46.94 | 23.53 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.